Research
Hormonal
Naltrexone/bupropion reduces food cravings and reward-driven eating by antagonizing opioid receptors, thereby decreasing the subjective delightfulness of energy-dense foods.
If you struggle with intense cravings for sugary or fatty foods, standard dieting may fail because your brain's reward system is driving your intake. Naltrexone/bupropion targets this by blocking opioid receptors, reducing the 'high' you get from these foods. This is prescribed alongside lifestyle changes for obesity management.
GoodSupportsHIGH confidence
Naltrexone antagonism of the opioid receptors has been reported as decreasing the subjective delightfulness or liking of particular foods; in particular, naltrexone plays a role in modulating the reward aspects of eating and the consumption of energy dense sugar and fat-laden foods [54–56].
Why this rating
Supported by phase-3 trials and specific questionnaires (CoEQ).
Source
Beyond Weight Loss: Added Benefits Could Guide the Choice of Anti-Obesity Medications
Valeria Guglielmi et al. · Current Obesity Reports · 2023
DOI 10.1007/s13679-023-00502-7
narrative_reviewCited 31×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (Liraglutide, Semaglutide) and Tirzepatide reduce food intake primarily by increasing satiety and reducing neural activation in brain areas associated with appetite and reward, rather than just delaying gastric emptying.Strong
- Tirzepatide, a dual GIP/GLP-1 receptor agonist, induces greater weight loss and improves glycemic control more effectively than GLP-1 RAs alone.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →